Humacyte, Inc. filed an underwriting agreement for a public offering of approximately 47.6 million shares of common stock with an additional 7.1 million shares as an optional greenshoe. The offering is being led by Barclays Capital Inc., BTIG, LLC, and Titan Partners Group LLC as representatives of the underwriting syndicate.